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Objective. To better define the activity of soluble
CXCL16 in the recruitment of polymorphonuclear neu-
trophils (PMNs) in vivo, utilizing a novel animal model
of gout involving engraftment of SCID mice with normal
human synovial tissue (ST) injected intragraft with
gouty human synovial fluid (SF).
Methods. For in vitro studies, a modified Boyden
chemotaxis system was used to identify CXCL16 as an
active recruitment factor for PMNs in gouty SF. Migra-
tion of PMNs could be reduced by neutralization of
CXCL16 activity in gouty SF. For in vivo analyses,
fluorescent dye–tagged PMNs were injected intrave-
nously into SCID mice while, simultaneously, diluted
gouty SF containing CXCL16, or depleted of CXCL16 by
antibody blocking, was administered intragraft. In ad-
dition, the receptor for CXCL16, CXCR6, was inhibited
by incubating PMNs with a neutralizing anti-CXCR6
antibody prior to injection into the mouse chimeras.
Recruitment of PMNs to the gouty SF–injected normal
human ST was then examined in this SCID mouse
chimera system.
Results. CXCL16 concentrations were highly ele-
vated in gouty SF, and PMNs were observed to migrate
in response to CXCL16 in vitro. Normal human ST–
SCID mouse chimeras injected intragraft with gouty SF
that had been depleted of CXCL16 during PMN transfer
showed a significant reduction of 50% in PMN recruit-
ment to engrafted tissue as compared with that after
administration of sham-depleted gouty SF. Similar find-
ings were achieved when PMNs were incubated with a
neutralizing anti-CXCR6 antibody before injection into
chimeras.
Conclusion. Overall, the results of this study
outline the effectiveness of the human–SCID mouse
chimera system as a viable animal model of gout,
serving to identify the primary function of CXCL16 as a
significant mediator of in vivo recruitment of PMNs to
gouty SF.
Gout develops as a result of synovial tissue (ST)
deposition of monosodium urate monohydrate (MSU)
crystals from supersaturated extracellular fluid. Urate
crystal deposition in the joints causes acute inflamma-
tory responses, which are set off by the negatively
charged crystal surfaces that activate complement (e.g.,
C5a, C3a), leading to the release of proinflammatory
cytokines and chemokines. Interleukin-8 (IL-8;
CXCL8), for example, is a chemokine and polymorpho-
nuclear neutrophil (PMN) recruitment factor that is
associated with gout (1,2). PMNs respond to CXCL8 via
its corresponding receptors, CXCR1 and CXCR2 (3). In
addition, in an experimental rabbit model of acute gouty
arthritis, studies of the knee joints of rabbits deficient in
membrane attack complex (MAC) component C6 re-
vealed that MAC activation appears to play a major role
in intraarticular CXCL8 generation and neutrophil re-
cruitment (4).
Inhibition of CXCL8 has been shown to be a
principal factor of PMN recruitment in animal models of
gout. For example, Nishimura et al showed that intraar-
ticular injection of a neutralizing anti-CXCL8 antibody
significantly attenuated crystal-induced joint swelling
and neutrophil infiltration in the rabbit knee (5). The
overall process is thought to involve MSU crystal depo-
sition that induces CXCL8 secretion and subsequent
recruitment of PMNs to the inflamed joints. In addition,
multiple CXCR2 ligands may exist in gouty synovial
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fluid (SF) that could account for some of the chemotac-
tic activities beyond those of CXCL8; for example,
growth-related oncogene /CXCL1 exhibited robust
neutrophil recruitment activity in a murine subcutane-
ous air pouch model of urate crystal–induced inflamma-
tion (3). Thus, chemokines and their cellular receptors,
especially CXCR2, have generated great interest as a
foundation for intervention strategies to reduce inflam-
mation.
Although therapeutic approaches to alter or re-
duce the activity of enzymes required for uric acid
formation in gout are currently being improved (6–14),
alternative strategies that target the chemokines or other
growth factors involved in PMN recruitment may also
show clinical potential. Because of the association of
MSU crystal formation with PMN recruitment and the
observed release of chemokines such as CXCL8 in gout,
there continues to be enormous interest in therapies that
block not only CXCL8 but also other chemokines that
may have proinflammatory activity in gout and many
other inflammatory disorders (1,2,15–20).
In the present study, we initially focused on
exploring new avenues of cytokine expression in gout,
with a principal spotlight on the chemokines involved in
the recruitment of mononuclear cells and/or PMNs. To
address this, we examined the expression of several CC
and CXC chemokines in gouty SF from human patients
(16,21). We observed that, in addition to CXCL8, the
chemokines expressed in gouty SF were interferon-–
inducible 10-kd protein/CXCL10, monocyte chemoat-
tractant protein 1/CCL2, and CXCL16. Because of its
unusually elevated concentrations in gouty SF, CXCL16
was set apart from the other chemokines for further
analysis.
To determine whether inhibition of CXCL16
could influence the migration of PMNs, samples of
gouty SF incubated with neutralizing anti-CXCL16
antibodies, as well as sham-depleted gouty SF samples
as controls, were tested in vitro using a Boyden chemo-
taxis chamber system. We also utilized a novel model of
crystal-induced arthritis that facilitated evaluation of the
effects of CXCL16 inhibition on migration of human
PMNs from the peripheral blood to engrafted human
ST. In this model, we injected gouty SF directly into
normal human ST that had been engrafted into SCID
mice, followed by intravenous (IV) injections of fluores-
cent dye–tagged PMNs (17). “Humanizing” the mice in
this way facilitated our analysis of actual gouty SF and
also provided clinical relevance, because it allowed us to
use human ST to quantify PMN recruitment in an in vivo
setting. The extent of PMN migration to engrafted
normal human ST in response to injected gouty SF was
evaluated and linked to the CXCL16 concentrations in
gouty SF.
MATERIALS AND METHODS
Collection of human SF and ST samples. For the
present study, we obtained SF from patients with gout, using
samples that are normally discarded from such patients during
therapeutic arthrocentesis, a procedure that was unrelated to
the current research. Prior to undergoing this surgery, patients
were asked whether they were willing to contribute SF to the
study. The presence of gout in the SF was confirmed by crystal
detection. Specimens of gouty SF were aliquoted and stored at
80°C until used. All specimens were obtained with Institu-
tional Review Board approval.
For samples of human ST, the Cooperative Human
Tissue Network and National Disease Research Interchange
were utilized to obtain cadaveric normal human ST specimens.
Normal human ST was obtained primarily from the knees of
donors, and all samples were processed within 24 hours of the
donor’s death. The ST samples were screened, and the tissue
was considered normal if the donors were not previously
diagnosed as having a rheumatic disease, such as rheumatoid
arthritis (RA) or osteoarthritis. Under sterile conditions, the
normal human ST was isolated from surrounding tissue, cut
into 0.5-cm3 segments, and screened for pathogens before
being implanted into SCID mice. All tissue samples were
stored frozen at 80°C in a freezing medium (containing 80%
heat-inactivated fetal bovine serum with 20% [volume/volume]
dimethyl sulfoxide). Prior to insertion into the mice, the frozen
samples were thawed and washed 3 times with phosphate
buffered saline (PBS). The rate of recovery of tissue using this
method is 100%. All specimens of human ST were obtained
with Institutional Review Board approval.
SCID mice. SCID/NCr mice were purchased from the
National Cancer Institute. All mice were maintained in a
pathogen-free animal facility and given food and water ad
libitum.
Enzyme-linked immunosorbent assay (ELISA) tech-
nique. ELISAs were performed in a manner as described
previously (20) to assess gouty SF for the presence of chemo-
kines not available on the Luminex panels. Briefly, levels of
IL-1, CXCL8, and CXCL16 were measured by coating 96-
well polystyrene plates with anti-human chemokine antibodies
(R&D Systems) followed by a blocking step. All samples were
added in triplicate, with recombinant human chemokine
(R&D Systems) used as standard. Subsequently, biotinylated
anti-human antibody and streptavidin–peroxidase were added,
and the concentrations in each sample were measured at 450
nm after developing the reaction with tetramethylbenzidine
substrate. The correlation coefficient for detection of each
chemokine in the ELISAs was 0.99, with a sensitivity (usually
at a concentration of 15 pg/ml) that was well below the
average concentrations of IL-1, CXCL8, or CXCL16 in gouty
SF.
Luminex assay. Luminex is a technique that combines
flow cytometry analysis and ELISA. Luminex was performed
with kits from BioSource International and used in accordance
with the manufacturer’s instructions. The accuracy of the
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Luminex data has been confirmed. It should be noted that we
did not use the plateau part of the concentration curve; rather,
we used the data in the middle of the curve, with a linear
correlation coefficient of 0.99. Similar results were obtained by
ELISA. A panel of cytokines was measured by Luminex assay
in the gouty SF, including measurements of fractalkine
(CX3CL1), granulocyte colony-stimulating factor (G-CSF),
IL-17, CXCL10, CCL2, macrophage inflammatory protein 1
(MIP-1/CCL3), MIP-1/CCL4, tumor necrosis factor 
(TNF), and vascular endothelial growth factor (VEGF).
SF neutralization studies. For neutralization of
CXCL16, diluted SF (1:300 with PBS) was preincubated with a
neutralizing polyclonal goat anti-human CXCL16 antibody
(catalog no. AF976; R&D Systems) at a concentration of 135
ng/100 l diluted SF (from undiluted gouty SF samples
containing 25 ng/ml CXCL16). Control (sham-depleted)
gouty SF samples were incubated in a similar manner but with
a corresponding control nonspecific antibody (goat IgG; R&D
Systems), as recommended by the vendor and previously
described in experiments with RA SF (20). Similarly, for
neutralization of human CXCL10, a goat anti-human CXCL10
antibody was used (catalog no. AF-266-NA; R&D Systems),
and the control antibody was also goat IgG. Only those SF
samples expressing average concentrations of the chemokines
(typically, 25 ng/ml for CXCL16 and 304 pg/ml for
CXCL10) were used. PMNs were then evaluated in chemotaxis
assays in vitro and in PMN migration studies in vivo, as
described below.
PMN isolation and fluorescent dye incorporation.
Human PMNs were isolated from the peripheral blood (100
ml) of normal healthy adult volunteers, and the cells were
applied to Ficoll gradients in a manner as described previously
(22). Both the viability and the purity of the cells were
routinely 98%. For in vivo studies, PMNs were fluorescent
dye–tagged with PKH26 fluorescent dye, in accordance with
the manufacturer’s instructions (Sigma). Successful labeling of
PMNs was confirmed by performing cytospin analysis and
observing fluorescing PMNs under a microscope equipped
with a 550-nm filter.
In vitro migration assay. Chemotaxis assays were
performed using a 48-well modified Boyden chamber system,
as previously described (20,23). For studies using gouty SF, all
samples were centrifuged, diluted, and centrifuged again be-
fore use in in vitro assays. Sham-depleted control and
antibody-blocked gouty SF samples were processed in a similar
manner. Briefly, a stimulant (25 l) of either CXCL16 or
diluted gouty SF (1:300 in PBS) was added to the bottom wells
of the chambers, while 40 l of PMNs at 1  106 cells/ml was
placed in the wells at the top of the chambers. Sample groups
were assayed in quadruplicate, with the results expressed as the
mean  SEM number of cells migrated per high-power field
(at 400 magnification). Hank’s balanced saline solution
(HBSS) and FMLP (at 107M) were used as negative and
positive controls, respectively.
Generation of normal human ST–SCID mouse chime-
ras. Normal human ST–SCID mouse chimeras represent a
unique way to study human tissue in vivo. We used this model
to study whether gouty SF, some of which was depleted of
CXCL16, can recruit PMNs in vivo. Six-to-8–week-old immu-
nodeficient mice were anesthetized with isoflurane under a
fume hood, and a 1.5-cm incision was made with a sterile
scalpel on the midline of the back. Forceps were used to blunt
dissect a path for insertion of the ST graft. Each ST graft was
implanted on the graft bed site and sutured using surgical
nylon. Grafts were allowed to “take” and the sutures removed
after 7–14 days.
Within 4–6 weeks of graft transplantation, unpooled
diluted gouty SF (1:300 in PBS) was injected into the graft. For
studies using the gouty SF, all samples were centrifuged,
diluted, and centrifuged again before administration into chi-
meras. Sham-depleted and antibody-blocked gouty SF samples
were processed in a similar manner. Purified gouty SF, either
CXCL16-depleted (with a specific neutralizing anti-human
CXCL16 antibody; R&D Systems) or sham-depleted (with a
nonspecific IgG; R&D Systems), was injected directly into the
normal human ST grafts using a 23-gauge needle. For some
studies, PMNs were incubated with monoclonal mouse anti-
human CXCR6 receptor antibodies (125 g/ml mouse anti-
human CXCR6 antibody added to 0.5 ml PMNs at 5  106
PMNs/100 l) (catalog no. MAB699; R&D Systems). Control
PMNs were incubated in a similar manner, except that a
nonspecific mouse IgG was used, before injection into chime-
ras. Mice were killed, and the grafts were harvested 48 hours
later. For all in vivo studies, PMNs integrated into the im-
planted ST were examined using a fluorescence microscope on
slides containing cryosections of graft tissue, and scores for
PMN migration were assigned. All sections were analyzed by
evaluators who were blinded to the experimental setup.
Statistical analysis. Statistically significant differences
between groups were calculated using Student’s t-test. P values
less than 0.05 were considered significant. All statistical data
are expressed as the mean  SEM.
RESULTS
Measurement of cytokines in gouty SF by Lumi-
nex and ELISA. In gouty SF, the concentrations of
chemokines CXCL10 and CCL2 and the angiogenic
factor VEGF were significantly up-regulated as com-
pared with the other cytokines measured (Figure 1A).
The mean  SEM concentrations of CXCL16 and
CXCL8, as measured by ELISA (Figure 1B), were at
least 100-fold higher for CXCL16 and 10-fold higher for
CXCL8 in comparison with the other cytokines mea-
sured. In addition, neither TNF nor the lymphokine
IL-17 was detected in the gouty SF.
Induction of PMN migration by CXCL16. Nor-
mal human peripheral blood PMNs were assayed in a
modified Boyden chamber for their chemotactic re-
sponse to CXCL16, to determine whether CXCL16 has
a proinflammatory role in gout; FMLP and HBSS served
as positive and negative controls, respectively. CXCL16
induced chemotaxis of human PMNs in a dose-
dependent manner, and PMN migration was maximal in
response to CXCL16 concentrations between 1.0 nM
and 10.0 nM (n  6 gouty SF samples per group) (Figure
2A). To determine the participation of CXCL16 in PMN
migration in gout, samples of gouty SF containing
average levels of CXCL16 (25 ng/ml, before dilution of
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1:300 in PBS) were incubated with an anti-human
CXCL16 antibody. The SF samples were then tested in
an in vitro migration assay and compared with sham-
depleted controls. Gouty SF showed an 20% decrease
in PMN migratory activity (P  0.05 versus controls)
after incubation with the neutralizing CXCL16 antibody
(Figure 2B).
We also examined the role of CXCL10 as an
alternative CXC chemokine, since, similar to the expres-
sion patterns of CXCL8 and CXCL16, it was also
Figure 1. Cytokine measurements in gouty synovial fluid (SF) by
Luminex assay and enzyme-linked immunosorbent assay (ELISA). A,
In the Luminex analyses, chemokines CXCL10 and CCL2 and the
angiogenic factor vascular endothelial growth factor (VEGF) were
found to be significantly up-regulated as compared with the other
cytokines measured. All values shown are the final concentrations
observed in undiluted gouty SF. B, ELISA measurements indicated
that the concentration of CXCL16 was at least 100-fold higher than
that of the other cytokines measured in gouty SF. The concentration of
CXCL8 was also elevated as compared with many other cytokines, but
it was 10-fold less abundant than CXCL16 in gouty SF. Of note,
tumor necrosis factor  (TNF) and interleukin-17 (IL-17) were not
expressed in the gouty SF. Bars show the mean and SEM. G-CSF 
granulocyte colony-stimulating factor. Color figure can be viewed in
the online issue, which is available at http://www.arthritisrheum.org.
Figure 2. Migration of polymorphonuclear neutrophils (PMNs) to-
ward CXCL16 in vitro. A, CXCL16 induced chemotaxis of human
PMNs in gouty synovial fluid (SF) in a dose-dependent manner and
was maximal at CXCL16 concentrations between 1.0 nM and 10.0 nM
(n  6 samples per group). Hank’s balanced saline solution (HBSS)
served as a negative control. B, Blocking of CXCL16 with a neutral-
izing anti-CXCL16 antibody in gouty SF reduced the in vitro PMN
chemotactic activity of the gouty SF. C, Antibody blocking of CXCL10
in gouty SF showed that PMNs failed to migrate toward CXCL10 in
vitro, and thus CXCL10 did not induce chemotaxis of human PMNs at
concentrations similar to those observed in gouty SF. Goat IgG served
as a control nonspecific antibody. Bars show the mean and SEM.
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observed to be highly up-regulated relative to the other
cytokines analyzed in gouty SF (Figure 1A). Because the
role of the CXCL8–CXCR2 ligand–receptor pair in
PMN chemotaxis is already well established (3), we
compared CXCL16-mediated chemotaxis with that of
CXCL10 in gouty SF, with the use of antibody-blocking
studies. Comparison of CXCL16-mediated PMN che-
motaxis with the activity of CXCL10, the latter of which
is not known to recruit PMNs but, rather, is known to
recruit monocytes, T cells, natural killer cells, and den-
dritic cells, serves as a natural negative control for
CXCL16-mediated PMN chemotaxis. Accordingly, un-
like the findings with regard to CXCL16, we observed no
effect on PMN chemotaxis in vitro upon blocking of
CXCL10 (Figure 2C), confirming that not all CXC
chemokines are effective PMN recruitment factors in gout.
PMN recruitment to engrafted human ST in a
SCID mouse chimera. To test PMN migration in vivo,
we used engraftment of a SCID mouse chimera with
normal human ST (diagram of the procedure is shown in
Figure 3A). After 4–6 weeks, the mice engrafted with
normal human ST and showing no signs of graft rejec-
tion were used (Figure 3B). To determine homing of
normal human PMNs, freshly isolated cells were fluo-
rescent dye–tagged with PKH26, and 5  106 cells/100
l/mouse were injected IV by tail vein 48 hours before
the mice were killed. Cryosections (10 m) of the
normal human ST grafts were then examined using a
fluorescence microscope. SCID mice engrafted with
normal human ST that was injected intragraft with
diluted (1:300 in PBS) gouty SF showed robust recruit-
ment of IV-administered, fluorescent dye–tagged PMNs.
Figure 3. A, Procedure used to produce an animal model of gout involving SCID mouse chimeras.
Normal (NL) human synovial tissue (ST) was engrafted into SCID mice, followed by intragraft
administration of diluted gouty human synovial fluid (SF) (diluted 1:300 with phosphate buffered
saline; 100 l/graft) and intravenous injection of PKH26 red fluorescent dye–tagged human
polymorphonuclear neutrophils (PMNs) (5  106). Simultaneous inhibition experiments involved
antibody blocking of CXCL16 in the gouty SF or depletion of CXCR6 from the PMNs. B, A
representative normal human ST–SCID mouse chimera at 4–6 weeks after engraftment is shown.
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These results indicate that exogenously administered
gouty SF containing CXCL16, as well as many other
PMN chemotactic factors, will induce recruitment of
human PMNs in the SCID mouse chimera system.
Reduction in PMN recruitment in vivo by anti-
body blocking of CXCL16 in gouty SF. Dye-tagged
PMNs were allowed to migrate for 48 hours to human
ST grafts injected with gouty SF (diluted 1:300 in PBS).
The tissue grafts were then harvested, snap-frozen, and
cryosectioned. Dye-tagged migrated cells were observed,
using a fluorescence microscope, in the normal human
ST grafts (Figure 4A). Normal human ST–SCID mouse
chimeras injected intragraft with gouty SF that had been
preincubated with blocking antibodies to CXCL16 at the
time of PMN transfer showed a 50% reduction in PMN
recruitment to the grafts as compared with controls
injected with sham-depleted gouty SF (Figure 4B). This
finding is consistent with the results from our in vitro
studies and further demonstrates that the extent of
CXCL16 expression is correlated with PMN recruitment
to gouty SF.
Figure 4. Reduction of polymorphonuclear neutrophil (PMN) re-
cruitment in vivo by inhibition of CXCL16 with a neutralizing anti-
CXCL16 antibody in gouty synovial fluid (SF). A, PKH26 red fluores-
cent dye–tagged human PMNs were injected intravenously into SCID
mice engrafted for 4–6 weeks with normal (NL) human synovial tissue
(ST). Before administration of the cells, ST grafts were injected with
gouty SF that was either blocked with neutralizing anti-CXCL16
antibodies or sham-depleted with nonspecific IgG. At 48 hours, grafts
were harvested and tissue sections were examined using immunofluo-
rescence microscopy at an optical density of 550 nm (original magni-
fication  400). B, Migration of the PMNs was quantified by dividing
the number of cells per high-power field (hpf) (counted at 100
magnification) in each ST tissue section. Bars show the mean and SEM
number of ST sections counted (from a total of 5 mice per group).
Color figure can be viewed in the online issue, which is available at
http://www.arthritisrheum.org.
Figure 5. Reduction of polymorphonuclear neutrophil (PMN) re-
cruitment to normal human synovial tissue by inhibition of CXCR6 in
PMNs in the gouty SCID mouse chimera model. A, The number of
PMNs (arrow) per high-power field (hpf), counted at 100 magnifi-
cation on fluorescence microscopy, was dependent on the size and
composition of the graft and corresponding section. The entire area of
each tissue section was counted. Approximately 60–90 hpfs were
counted per implant, from at least 5 independently grafted mice in
each group (IgG controls versus anti-CXCR6–treated mice). The total
number of sections from each mouse constituted the number of
samples (e.g., 15 sections/graft from 3 grafts is 45 sections). Grafts
were surgically removed and set in histology blocks containing OCT.
Grafts composed of significant amounts of murine tissue were ex-
cluded from the study. B, Migration of the PMNs was quantified by
dividing the number of cells per high-power field. Bars show the
mean and SEM number of synovial tissue sections counted. Color
figure can be viewed in the online issue, which is available at
http://www.arthritisrheum.org.
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Reduction in PMN recruitment to normal human
ST injected with gouty SF by antibody blocking of
CXCR6. PMNs were incubated with a neutralizing anti-
CXCR6 antibody, and the cells were then fluorescent
dye–tagged and injected IV into SCID mouse chimeras
that had received intragraft injections (100 l/graft) of
diluted gouty SF (1:300 in PBS). After 48 hours, the
mice were killed, and the grafts were removed for
cryosectioning. Control mice received the same intra-
graft injection of gouty SF but were administered fluo-
rescent dye–tagged PMNs preincubated with nonspecific
IgG (Figure 5A). As shown in Figure 5B, mice admin-
istered PMNs preincubated with anti-CXCR6 showed a
42% reduction in PMN migration, which was a signifi-
cantly greater reduction as compared with that in control
mice.
DISCUSSION
Cytokine networks in gout have been insuffi-
ciently characterized, although some attempts have been
made in animal models (6,24–27). To identify significant
cytokine and chemokine systems, we examined several
cytokines by performing Luminex assays on gouty SF,
which allowed us to profile the cytokine expression
patterns in human patients. These analyses included
measurement of chemokines, a subset of cytokines that
work to induce cell migration to sites of inflammation
(16,19). The CC chemokines measured were CCL2,
CCL3, and CCL4. The CXC chemokines included
CXCL10, CXCL8, and CXCL16; the latter 2 were
measured by ELISA. We also examined CX3CL1, a
chemokine that is associated with mononuclear cell
recruitment and angiogenic activity in RA (20,28)
We showed that the concentrations of CXCL10,
CCL2, CXCL16, and the proangiogenic factor VEGF
were all up-regulated relative to a panel of other cyto-
kines measured. The levels of CCL2 measured in the
gouty SF samples were comparable with those described
in a previous study (29), and the extent of CCL2
expression likely accounts for many of the recruited
monocytes found in gouty SF. We also observed that
expression of the PMN growth factor G-CSF was up-
regulated in gouty SF.
Several of these cytokines are proinflammatory
mediators that are associated with cell recruitment to
joint tissue (16,19). VEGF and CXCL16 are associated
with angiogenesis, or new blood vessel growth. More-
over, VEGF has been implicated in wound repair (30),
and CXCL16 has been shown to be a very active
mononuclear cell recruitment factor in RA (17) and has
been shown to have angiogenic activity (31). According
to our preliminary profile, it is likely that, in addition to
CXCL8, the mediators measured in the present study
may all be important for cell infiltration to the joints of
patients with gout (3).
We also noted that IL-17 was not significantly
expressed in the samples of gouty SF, in accordance with
the paucity of lymphocytes observed in the gouty SF
(results not shown). Interestingly, TNF was also not
expressed in the gouty SF (n  7 different specimens
examined), suggesting that the cytokines up-regulated in
gout possibly function in a manner independent of
TNF. Expression of IL-1 was also relatively low in the
gouty SF, compared with the concentrations of CXCL8
or CXCL16, but has been shown to play a more central
role than TNF in experimental urate crystal–induced
inflammation (32,33). Indeed, favorable results with
IL-1 inhibitors to suppress pain and inflammation have
been observed in small, open-label studies in patients
with chronic, treatment-refractory gouty inflammation
(32–34).
CXCL16 was implicated in the early phases of
this study as a possible mediator of angiogenesis and cell
recruitment in gout. Our findings confirmed the pres-
ence of highly elevated levels of CXCL16 in gouty SF,
with measurements that were 100-fold greater than
those of many of the other cytokines present. CXCL16
also showed chemotactic properties with regard to
PMNs. Indeed, our in vitro chemotaxis findings showed
that CXCL16 appeared to be a very active PMN recruit-
ment factor in the 1.0 nM (10 ng/ml) to 10.0 nM (100
ng/ml) concentration range, consistent with the concen-
trations of CXCL16 observed in the gouty SF (Figure
2A).
For the in vivo phase of this study, we depleted
the cytokines that were observed to be up-regulated in
gouty SF and tested their PMN recruitment ability in the
SCID mouse chimera system. We observed that deplet-
ing either CXCL16 or membrane-bound CXCR6 in
gouty SF significantly inhibited the recruitment of PMNs
in vivo. Of note was the failure to observe complete
inhibition of PMN recruitment in the SCID mouse
chimera system. A plausible explanation for this may be
that there is incomplete up-regulation of CXCR6 in
PMNs, such that only basal levels of CXCR6 in PMNs
account for just a fraction of the total cellular CXCR6
(35). The findings from our experiments using unstimu-
lated PMNs, before incubation with anti-CXCR6, sup-
port this notion. Other factors contributing to incom-
plete in vivo suppression of PMN migration may be the
expression of complement byproducts or numerous un-
inhibited chemokines, such as CXCL8, that are also
prominent in gouty SF.
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Detection of VEGF in gouty SF was somewhat
unexpected. Gout is not thought of as a disease that is
dependent on a high degree of vasculature. However,
the cellular infiltrate observed in the gouty SF seemed to
indicate that the cells were migrating freely from the
peripheral bloodstream into the joint tissue, presumably
aided by additional vasculature mediated by VEGF
expression. Furthermore, monocytes respond, produce,
and migrate toward VEGF, providing further evidence
that recruited monocytes may amplify the angiogenic
process in gout.
It is tempting to speculate that the effects of
VEGF on vascular growth may exacerbate gout pathol-
ogy. A review of the current literature indicates only a
paucity of information linking gout and angiogenesis.
However, in a small study by Lapkina et al, possible
laboratory markers of vascular endothelium activation
were identified as being of clinical significance in gout
(36). Although those authors did not examine circulating
VEGF levels, they did, interestingly, show increased
serum concentrations of soluble vascular cell adhesion
molecule 1 and von Willebrand factor in patients with
gout. This reflected not only the activation of vascular
endothelium but also the development of atherosclerotic
processes in these patients (36). In accordance with this,
Schumacher demonstrated the expected robust neutro-
phil infiltrates in a gouty synovial biopsy specimen, and
also observed high vascularization of gouty human ST
(37). We propose that recruitment of PMNs and mono-
cytes to gouty tissue may rely heavily on neoangiogenic
responses induced by VEGF in gouty synovium, and
also possibly those induced by CXCL16 in gouty SF.
Since CXCL16 is an angiogenic mediator (31), mono-
cyte recruitment factor (17), memory T cell recruitment
factor (38), and PMN recruitment factor (35), CXCL16
may be a premiere proinflammatory mediator in gout,
and this role of CXCL16 would support our premise of
significant CXCL16 involvement in gout pathology.
With these experiments, we determined the ex-
pression and function of secreted chemotactic factors
and their impact on local PMN recruitment in gouty SF.
We have presented evidence to suggest that several
chemokines and chemokine receptors, apart from
CXCL8, may be at work in gout pathology. We observed
that CXCL16 concentrations are elevated in gouty SF
and that soluble CXCL16 is expressed at concentrations
much higher than those of CXCL8. This suggests that
soluble mediators other than CXCL8 may play a signif-
icant role in PMN recruitment caused by MSU crystal–
induced inflammatory responses. For this study, we
tested our initial in vitro findings with a novel in vivo
model of crystal-induced arthritis and related these
findings to the extent of CXCL16 expression. Although
other investigators have characterized some rudimen-
tary cytokine networks in gout (24), this study was novel
in that we examined the nature of PMN recruitment and
homing in a normal human ST–SCID mouse chimera.
These in vivo experiments built on our initial findings
by examining the activity of CXCL16 and its receptor,
CXCR6, in an in vivo setting. This allowed for the
evaluation of the architectural changes in engrafted
normal human ST due to PMN migration in response to
injected gouty fluid. Thus, we were able to mimic gout
pathology with an in vivo model that reproduces this
disease with accuracy, which will further the develop-
ment of therapeutic strategies designed to inhibit proin-
flammatory factors, such as CXCL16, that enhance
PMN recruitment to gouty tissue.
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